Kenvue's SWOT analysis: resilient brands face beauty segment challenges

Kenvue (KVUE), spun off from Johnson & Johnson in 2023, faces mixed performance with resilience in its Self Care and Essential Health segments but struggles in Skin Health & Beauty (SH&B); analysts project modest EPS growth of $1.14 for FY1 and $1.21 for FY2. Management's focus on marketing, innovation, and exiting Transition Service Agreements aims to achieve 3-4% sales growth and mid-to-high single-digit bottom-line growth, though challenges remain in the competitive beauty market and stabilizing the SH&B segment, which could be worth $7-13 per share if it achieves a 20% EBITDA margin and sales increase by 10% from depressed levels.

Analysis

Kenvue Inc. (NYSE:KVUE), following its 2023 spin-off from Johnson & Johnson, presents a mixed operational landscape with a market capitalization of approximately $46 billion as of May 2025. The company's Self Care and Essential Health segments demonstrate resilience and positive momentum, underpinning stability. However, the Skin Health & Beauty (SH&B) segment, particularly Neutrogena, has faced declining sales through Q3 2024 and market share losses, though nascent signs of recovery are emerging in EMEA and stabilization in the US. Analysts project modest EPS growth, with estimates of $1.14 for FY1 and $1.21 for FY2. Management's "Extraordinary Powers" strategy for FY25 focuses on increased marketing and innovation for its mega brands, alongside the crucial exit from Transition Service Agreements (TSAs) with Johnson & Johnson by mid-2025, which is anticipated to reduce costs. Long-term targets include 3-4% sales growth, mid-to-high single-digit bottom-line growth, and a dividend yield exceeding 3.5%. The SH&B segment, currently valued around $6 per share, holds potential to reach $7-13 per share if it achieves a 20% EBITDA margin and a 10% sales increase from current depressed levels. Key challenges include intense competition in the beauty sector, macroeconomic headwinds, and the complexities of full separation, including potential inherited product liabilities. The overall sentiment towards KVUE is mixed and cautious, with its future heavily reliant on the successful turnaround of the SH&B division and sustained performance in its other core segments.

Key Decisions for Investors

• Investors should closely monitor the Skin Health & Beauty segment's performance, particularly sales trends and market share for Neutrogena, as its recovery is critical to unlocking Kenvue's valuation potential and achieving management's growth targets.
• The successful and timely exit from Transition Service Agreements with Johnson & Johnson by mid-2025 is a key catalyst to watch, as it should lead to improved cost efficiencies and operational independence.
• Consider Kenvue's current valuation in light of its modest near-term EPS growth projections ($1.14 for FY1, $1.21 for FY2) against its long-term ambitions and the potential upside from the SH&B turnaround, balanced by execution risks and competitive pressures.
• Evaluate the stability offered by the Self Care and Essential Health segments, and the over 3.5% target dividend yield, as potential buffers while the SH&B segment undergoes its transformation.